We evaluated the validity and accuracy of cytomorphology and multiparametric flow cytometry (C-FCM) Traditionally, the technique of choice for diagnosing of lymph nodes was based on the histopathologic study of paraffin-embedded tissue. Currently, the use of immunohistochemical techniques for detecting cell-specific antigens is essential in classifying tumors, identifying prognostic factors, and identifying targets for therapy. 1 However, the pathologist's analysis of the results from immunohistochemical studies in routine clinical practice has limitations: analysis subjectivity, limited reproducibility, and the time invested. The interobserver and intraobserver variability are high because of the elevated number of factors that may interfere in processing the sample and because of the impact of the pathologist's interpretation of the results. 2,3 Furthermore, the lack of consensus in quantifying antigen expression and defining positive and negative results is one of the leading causes of nonreproducibility. These limitations justify the development of new diagnostic tools.
Traditionally, the technique of choice for diagnosing of lymph nodes was based on the histopathologic study of paraffin-embedded tissue. Currently, the use of immunohistochemical techniques for detecting cell-specific antigens is essential in classifying tumors, identifying prognostic factors, and identifying targets for therapy. 1 However, the pathologist's analysis of the results from immunohistochemical studies in routine clinical practice has limitations: analysis subjectivity, limited reproducibility, and the time invested. The interobserver and intraobserver variability are high because of the elevated number of factors that may interfere in processing the sample and because of the impact of the pathologist's interpretation of the results. 2, 3 Furthermore, the lack of consensus in quantifying antigen expression and defining positive and negative results is one of the leading causes of nonreproducibility. These limitations justify the development of new diagnostic tools.
Cytomorphologic examination and multiparametric flow cytometry (C-FCM) resolve some of these obstacles: a fast diagnosis, qualitative and quantitative analysis of cell antigens, and multiparametric analysis. However, C-FCM also has limitations: variability in the antigen signature of expression and cellular weakness during the processing, among others. 4, 5 Because of these limitations, centers with both diagnostic tools are using C-FCM as a complementary method to histopathologic study of the tissue.
C-FCM has proven to be an indispensable diagnostic and classification tool for chronic lymphoproliferative disorders with peripheral blood and bone marrow involvement. 6, 7 But C-FCM is valid not only for chronic lymphoproliferative disorders but also for other hematologic malignancies, including acute myeloid leukemia and lymphoblastic leukemia, in which histopathologic study is of little value. 8 This technique has also been proposed as the diagnostic method of choice in solid tissue samples obtained via fine-needle aspiration (FNA), especially in cases in which a conventional biopsy is impossible. Laane et al 9 studied 424 samples obtained via FNA from 396 patients with a suspicion of lymphoma. The majority of specimens were lymph node tissues. Immunophenotypic analyses were performed in all samples using immunohistochemical and FCM techniques with the following monoclonal antibodies: immunoglobulin light chain (ie, κ or λ), CD19, CD5, CD23, CD10, CD20, CD19, CD4, CD7, CD8, CD3, and bcl-2. FCM proved to be a very efficient diagnostic technique and properly classified low-grade B-cell non-Hodgkin lymphomas (B-NHL) (95% concordance) and diagnosed follicular hyperplasia (97% concordance). Concordance was significantly lower in high-grade B-cell NHL and in T-cell NHL (T-NHL; 78% and 53% respectively). 9 Meda et al 10 demonstrated that cytomorphology and FCM were valid and effective diagnostic tools, at least as an initial diagnostic approach to NHL. They reviewed a total of 280 FNA samples from lymphoid tissue: 155 lymphomas, 44 suggestive of lymphoma, and 81 reactive lymphocytosis. From a total of 110 cases that underwent a lymph node biopsy, they calculated sensitivity and specificity values of 95% and 85%, respectively. 10 We designed a study to evaluate the validity and certainty of C-FCM as a diagnostic test for oncohematologic diseases in biopsied lymph node tissue from patients with lymphadenopathies. The secondary aim was to know the efficiency of our procedure to properly subclassify NHLs and indicate in which conditions C-FCM was insufficient. By validating this technique, we hope to have a trustworthy and fast diagnostic tool. Throughout our study, we did not modify any routine clinical practices in our hematology, pathology, and surgery services.
Materials and Methods
We studied lymph node tissue from biopsies of patients with lymphadenopathies or tumors, independent of clinical suspicion. The samples were received from the main surgical centers in the Cantabria (province, Spain) health care services. Each sample was divided into 2 parts; simultaneously, 1 fresh sample was sent to the Hematology Laboratory and 1 in formaldehyde to the Department of Pathology. Samples with insufficient material for both diagnostic processes were excluded and sent solely to the histopathologic department.
The C-FCM study of the samples was performed following the diagnostic protocol of the cytology and cytometry section and performed by hematologists expert in cytology and FCM.
Cytologic Examination
Four touch imprints were taken from fresh samples. Two of them were stained with May-Grünwald-Giemsa. Then they were examined by 2 experienced cytohematologists (F.M. and O.A.). First, we evaluated the quality of the sample in terms of cellularity and cell conservation. If they were not adequate, the rest of the touch imprints were stained. Then we studied the morphologic characteristics of the hematologic and nonhematologic cells. If we detected Hodgkin cells on the touch imprints, we analyzed the CD30 antigen in one of the imprints following the alkaline phosphatase-anti-alkaline phosphatase technique to complete the study. Representative cases are shown in ❚Image 1❚, ❚Image 2❚, ❚Image 3❚, ❚Image 4❚, ❚Image 5❚, ❚Image 6❚, ❚Image 7❚, and ❚Image 8❚.
Immunophenotypic Analysis
The specimens were received fresh or in saline. Cellular suspension was obtained after manual disaggregation and resuspended in phosphate-buffered saline. Cell suspension aliquots were incubated with the following monoclonal antibody panels ❚Table 1❚: CD4-fluorescein isothiocyanate (FITC)/CD8-phycoerythrin (PE)/CD3-peridinin chlorophyll protein (PerCP)/CD45-allophycocyanin (APC), CD5-FITC/ CD19-PE/CD20-PerCP/CD45-APC, CD20-FITC/CD10-PE/ CD19-PerCP/CD45-APC, and κ-FITC/λ-PE/CD19-PerCP. The incubation process, lysis, and washes were carried out following the manufacturer's recommendations (Becton Dickinson Biosciences, San Jose, CA). Cell acquisition was performed with the FACSCalibur (FACScan flow cytometer) and cell analysis with Paint-A-Gate software (Becton Dickinson Biosciences).
❚Image 1❚ Lymph node infiltration by diffuse large B-cell lymphoma (May-Grünwald-Giemsa, ×100).
When an aberrant immunophenotype was detected, we completed the study as follows: (1) If phenotypically abnormal cells belonging to the B-cell lineage were detected, the following combinations of monoclonal antibody panels were used ❚Table 2❚: FMC7-FITC/CD5-PE/CD19-PerCP, CD22-FITC/CD23-PE/CD19-PerCP, CD103-FITC/CD25-PE/ CD19-PerCP, CD10-FITC/CD11c-PE/CD19-PerCP, CD38-FITC/CD20-PE/CD19-PerCP, CD30-FITC/CD20-PE/CD45-PerCP, CD138-FITC/CD56-PE/CD19-PerCP, CD43-FITC/ CD19-PE, CD79a-FITC/CD19-PE, CD79b-FITC/CD19-PE, and bcl-2-FITC/CD10-PE/CD20-PerCP/CD38-APC. (2) If phenotypically abnormal cells belonging to the T-cell lineage were detected, the following combinations of monoclonal antibody panels were used (Table 2) : CD2-FITC/CD7-PE/ CD4-PerCP/CD8-APC, CD5-FITC/CD7-PE/CD4-PerCP/ CD8-APC, CD38-FITC/CD11b-PE/CD4-PerCP/CD8-APC, CD57-FITC/CD11c-PE/CD4-PerCP/CD8-APC, CD16-FITC/ CD56-PE/CD4-PerCP/CD8-APC, CD25-FITC/CD22-PE/ CD4-PerCP/CD8-APC, CD45RA-FITC/CD45RO-PE/CD4-PerCP/CD8-APC, CD57-FITC/CD56-PE/CD4-PerCP/CD8-APC, and CD20-FITC/CD10-PE/CD45-PerCP/CD5-APC.
The diagnosis of NHL was based on immunophenotypic information: (1) aberrant B-cell antigen expression and immunoglobulin light chain class and (2) aberrant T-cell and ❚Image 2❚ Lymph node infiltration by small cells with scant cytoplasm and prominent nuclear clefts (May-Grünwald-Giemsa, ×40).
❚Image 3❚ Binucleated large Reed-Sternberg cell shown in this view of the infiltrate (Wright-Giemsa, ×63).
❚Image 4❚ The Reed Sternberg cell (May-Grünwald-Giemsa, ×100).
❚Image 5❚ Clump of neuroblastoma cells (May-Grünwald-Giemsa, ×100).
NK-cell antigen expression. 11 Morphologic findings constituted the other available information. A Hodgkin lymphoma (HL) diagnosis was based on the presence of Hodgkin cells in the touch imprint without phenotypic abnormalities. The diagnosis of other hematologic neoplasia based on the morphologic findings was completed with other antibody panels ( Table 2) .
The diagnosis of nonhematologic neoplasia was based on the presence of malignant nonhematologic cells in the touch imprint without phenotypic abnormalities. When neuroblastoma was suspected, we completed the study with the following antibodies: CD56-FITC/CD45-PE/CD3-PerCP/CD9-APC.
These diagnostic categories were considered positive results for our diagnostic testing. When pathology was not detected in the cytologic and the immunophenotypic analyses, the samples were considered nondiagnostic and, thus, negative for our diagnostic testing.
Histopathologic Study
The samples were immediately fixed in 10% neutral buffered formalin and sent to the pathology laboratory. Fixing time varied relative to the size of the sample (6-24 hours). After the sample was dehydrated, it was embedded in paraffin and cut (4 μm). Finally, it was stained with H&E and, if necessary, a paraffin-section immunohistochemical study was performed (CD45, CD3, CD10, CD20, CD79a, bcl-2, bcl-6, CD15, CD30, p53, epithelial membrane antigen, cytokeratin, Ki-67, cyclin D1, p53, c-erb-B2, estrogen receptor, and progesterone receptor).
Macroscopic and microscopic examinations were performed by pathologists expert in oncohematology (F.M. and O.A.). C-FCM and histopathologic studies were performed ❚Image 6❚ Metastatic melanoma cells (May-Grünwald-Giemsa, ×100).
❚Image 7❚ Metastatic prostatic carcinoma. A group of homogeneous cells is noted. These cells have a slightly basophilic cytoplasm (May-Grünwald-Giemsa, ×100).
❚Image 8❚ Bronchioloalveolar carcinoma (May-Grünwald-Giemsa, ×63). To control information bias, we collected the sample entry date and final report delivery date from the Department of Hematology and the Department of Pathology. Finally, we had a series of 223 lymph node samples from patients with lymphadenopathies evaluated by C-FCM and corresponding histopathologic study. The clinical and demographic characteristics of the patients represented in the study are shown in ❚Table 3❚.
Validation Studies and Statistical Methods
To determine the validity of our diagnostic process, we calculated sensitivity and specificity parameters. In our study design, patients were classified as "Sick" if histopathologic study found the presence of neoplasia (hematologic or nonhematologic) or "Healthy" if the histopathologic diagnosis determined the process was benign or reactive. The criteria for defining C-FCM results as positive or negative were explained in the "Immunophenotypic Analysis" section.
With the sensitivity and specificity parameters, we calculated the probability of a positive or negative result relative to separately and in a blinded manner. The cases of NHL were subclassified following the 2001 World Health Organization (WHO) classification of hematolymphoid neoplasms. 12 
Study Design
We designed a prospective study of a diagnostic test. With an estimated sensitivity of 70% and a disease prevalence of 38% (confidence interval [CI] of 95%), we calculated a sample size of 214 samples with 10% precision. Our department previously carried out a pilot study reviewing the diagnoses of 715 lymph nodes sent to our laboratory between 1993 and 2003 from patients with lymph nodes under study. The benign and malignant diagnoses gave us the prevalence of oncohematologic disease in biopsied patients along with an initial approximation of the usefulness of C-FCM as a diagnostic tool for lymph nodes. 13 Between January 2004 and October 2007, we prospectively analyzed 237 samples, of which 14 were considered inadequate: 6 hypocellular samples, 4 necrotic samples, and 4 samples without simultaneous histopathologic study. B cell  FMC7  CD5  CD19  -CD22  CD23  CD19  -CD103  CD25  CD19  -CD10  CD11c  CD19  -CD38  CD20  CD19  -CD30  CD20  CD45  -CD138  CD56  CD19  -CD43  CD19  --CD79a  CD19  --CD79b  CD19  --bcl-2  CD10  CD20  CD38  T cell  CD2  CD7  CD4  CD8  CD5  CD7  CD4  CD8  CD38  CD11b  CD4  CD8  CD57  CD11b  CD4  CD8  CD16  CD56  CD4  CD8  CD25  CD22  CD4  CD8  CD45RA  CD45RO  CD4  CD8  CD57  CD56  CD4  CD8  CD20  CD10  CD45  CD5  Myeloid cell  HLA-DR  CD117  CD45  CD34  CD2  CD56  CD45  CD34  CD65  CD7.1  CD45  CD34  CD61  CD33  CD45  CD34  HLA-DR  CD123  CD45  CD34  CD71  Glycophorin  CD45  CD34  CD15  CD13  CD45  CD34  CD64  CD14  CD45  CD34  CD33  CD11b  CD45  CD34  cTdT  cMPO  CD45  CD34  Plasma cell  CD138  CD56  CD45  CD38  CD38  CD56  CD19  CD45  c κ  cλ  -CD38 APC, allophycocyanin; cκ, cytoplasmic κ; cλ, cytoplasmic λ; cMPO, cytoplasmic myeloperoxidase; cTdT, cytoplasmic terminal deoxynucleotidyl transferase; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PerCP, peridinin chlorophyll protein. * Panels are constructed by using the antibodies in the row combined with the column heading, eg, FMC7-FITC/CD5-PE/CD19-PerCP. the patient's real situation (has the disease or not). In addition, we calculated the positive and negative predictive values that determine the accuracy of C-FCM. To determine a valuation index that does not depend on prevalence, we also estimated the positive and negative likelihood ratios. This index measures how probable a result is positive (or negative) relative to the existence of a disease (or inexistence of disease).
Statistical analysis was performed to control for possible confounding variables such as age (analysis of variance), sex (χ 2 ), and lymph node location (χ 2 ). There were no significant differences due to age, sex, and lymph node location in the number of cases classified as true-positives, true-negatives, false-negatives, and false-positives.
Statistical analysis was performed with EPIDAT (version 3.1; Pan American Health Organization, Washington, DC) and SPSS software (version 15; SPSS, Chicago, IL). The C-FCM diagnosis was obtained significantly faster than the histopathologic diagnosis: 1.4 vs 7.5 days. Concordance between a positive result in C-FCM and the histopathologic diagnosis was excellent (97%).
C-FCM analysis provided a diagnosis of neoplasia in 133 samples. The C-FCM analysis was in agreement with the histopathologic diagnosis in 130 cases. In only 3 cases did discrepancies arise: (1) A diagnosis of follicular lymphoma was suggested by C-FCM; however, pathologic analysis supported a diagnosis of follicular hyperplasia. (2) A diagnosis of peripheral T-cell lymphoma was suggested by C-FCM; however, pathologic analysis supported a diagnosis of T-cell/ histiocyte-rich B-cell lymphoma (TCRBCL). (3) A diagnosis of HL was suggested by C-FCM; however, pathological analysis supported a diagnosis of TCRBCL.
A negative C-FCM analysis for neoplasia must be corroborated by a histopathologic study. In 90 of 223 samples, the C-FCM analysis did not show the presence of neoplasia, but it was confirmed in 17 cases (19%) by histopathologic study: 4 cases of B-NHL (2 TCRBCLs and 2 marginal zone lymphomas/mucosa-associated lymphoid tissue), 1 case of angioimmunoblastic T-NHL, 3 cases of HL, 1 case of granulocytic sarcoma, 1 case of Kaposi sarcoma, and 7 carcinomas.
Therefore, the estimated sensitivity of C-FCM for diagnosing neoplastic pathology in a lymph node sample was 87.25% (95% CI, 81.5%-93%) with a specificity of 96% (95% CI, 90.78%-100%). The validity, confidence, and likelihood parameters are shown in ❚Table 4❚. These parameters significantly improved by excluding cases of HL and malignant nonhematologic neoplasms.
The level of overall concordance between diagnostic techniques for subclassifying NHL according to WHO (secondary aim) was 87% in B-NHL. The level of concordance within each WHO category and associated discordant findings (11 cases) are shown in ❚Table 5❚. This analysis was not performed on T-NHL cases because of an insufficient number of cases (6 cases: 3 peripheral T-cell lymphomas, unspecified; 1 angioimmunoblastic T-cell lymphoma; 1 T-cell prolymphocytic leukemia; and 1 T-lymphoplasmacytic lymphoma).
Discussion
The aim of a study on diagnostic tests is to distinguish between normal and pathologic and to provide sufficient information to make a clinical decision relative to the specific test results. With the C-FCM, we obtained an 87.25% probability that a patient's biopsy specimen with neoplastic pathology would be positive. The majority of false-negatives corresponded to patients with carcinoma or HL. Sensitivity rose to 94.79% when we excluded the analysis of the latter 2 cases. This result was expected because the monoclonal analysis of the polyclonal light chains. From a clinical viewpoint, the patient was asymptomatic and without other swollen lymph nodes besides the single cervical lymph node. Because of the diagnostic discrepancy, clinical follow-up was done. After 1 year of follow-up, the patient shows no evidence of the disease. The clonal B-cell population detected by C-FCM in this biopsy sample could correspond to an incipient form of in situ follicular NHL, 15 in which the histopathologic result is usually normal and only very sensitive techniques like FCM and molecular study can make the diagnosis. Two of the cases with a diagnosis of TCRBCL in histopathologic analysis were classified as HL and as peripheral T-NHL in another. With C-FCM, no clonal B-cell population was detected in either of the cases. This discrepancy is considered significant because it modifies the therapeutic decision and prognosis for the patients. HL and TCRBCL share morphologic characteristics and probably biologic characteristics, too. There is usually less than a 10% lymphoid clonal B-cell population, and it is often accompanied by a cytotoxic lymphoid T-cell expansion, which complicates the differential diagnosis. 16 In fact, these 2 cases required a molecular antibody panel used in our routine clinical practice is not aimed at diagnosing nonhematologic diseases. The specificity of our procedure was more than 95%, which is similar to other studies. With these results, we can conclude that the combination of cytologic and FCM studies provides a valid diagnostic test.
In a study by Martínez et al, 14 sensitivity improved from 72% to 90% when excluding the HL.
The positive predictive value was more than 95% in both of our analyses. The probability that our patients have hematologic neoplasia when C-FCM is positive is sufficiently high to be able to make a quick clinical and therapeutic decision. This advantage, relative to histopathologic study, is fundamental in patients with disease with an aggressive course.
In a case labeled as follicular hyperplasia by histopathologic study, C-FCM detected 45% CD10+ κ B lymphocytes with a typical follicular NHL antigenic profile. The study for bcl-2 reordering was negative using fluorescence in situ hybridization (FISH). The sample was sent to a national cancer research center that supported the diagnosis of follicular hyperplasia, based on a paraffin-section immunohistochemical could not be performed. The existence of cyclin D1-MCL has been described, and only gene expression studies would support this diagnosis. 19 Of the 4 Burkitt lymphomas (BLs) diagnosed by C-FCM, 3 were confirmed by histopathologic study and 1 could not be subclassified. In this latter case the t(8;14) by FISH was negative. Owing to the clinical aggressiveness of the lymphoma, it was treated as if it was a BL, obtaining a satisfactory response to the standard chemotherapy treatment for BLs. Although in our study C-FCM was an effective technique for diagnosing BL, morphologic and phenotypic features often overlap with DLBCL, making a differential diagnosis difficult. For these cases, molecular study is necessary. 20 C-FCM is a valid and accurate diagnostic technique, specially in NHLs in which it also allows for their subclassification. It is faster than histopathologic study. These qualities allow us to make a suitable therapeutic decision quickly. However, in samples in which C-FCM cannot establish a diagnosis, we must wait for the histopathologic study. C-FCM is not a suitable technique for diagnosing TCRBCL or HL. study to establish the definitive diagnosis. Therefore, the HL and TCRBCL are still common diagnostic problems for most C-FCM laboratories because of the intrinsic characteristics of the Reed-Sternberg cell and the scarce clonal B-cell population of TCRBCL. A recent study has shown that with multicolor flow cytometry, a characteristic phenotype of an isolated Hodgkin cell can be identified via sorting. 17 With the acquisition of 0.5 to 1 × 10 6 events, it is very probable that we could identify the neoplastic population in TCRBCL. However, both diagnostic procedures are not part of the routine clinical practice in a diagnostic laboratory. This is why histopathologic study continues to be the diagnostic technique of choice.
The negative predictive value was low (78.78%) when including all neoplasias and improved to 93.42% when nonhematologic neoplasias and HL were excluded. Up to 18% of the biopsy specimens from patients with cancer may have an unaltered C-FCM result, but fewer than 5% of patients with an NHL will have a normal study result.
C-FCM properly classified 87% of B-NHLs. In the small lymphocyte NHL subgroup, concordance was 100%. The follicular NHL group had a concordance of 91%. Of the 35 cases classified as follicular NHL by C-FCM, there were only discordant results with histopathologic study in 3 cases. One case was the previously discussed follicular hyperplasia, and 2 were subclassified as diffuse large B-cell lymphoma (DLBCL). One of them revealed the t(14;18) by FISH. It corresponded to a follicular NHL in transformation to a DLBCL. Of the 22 DLBCLs diagnosed with C-FCM, 18 cases were confirmed by histopathologic study. The 4 discordant results in this group corresponded to 3 grade III follicular NHLs and 1 lymphoplasmacytic NHL. The 3 cases of grade III follicular NHL suggested by pathologic analysis were CD10-, without overexpression of cbcl-2 (intracytoplasmic) with the FCM and with a predominance of large cells in the touch imprint. FISH studies did not detect bcl-2 or bcl-6 rearrangements. Because both processes share oncogenic mechanisms and express very similar phenotypes and genetic alterations, the differential diagnosis in these cases requires molecular studies. 18 Of the 8 mantle cell NHLs (MCLs) diagnosed with C-FCM, 2 cases were not confirmed by histopathologic study. The histopathologic study could not subclassify one of these cases and called it "unspecified B-NHL." In the other case, it established the diagnosis of DLBCL. Both cases presented a typical antigenic expression pattern of MCL (CD5+/CD20+/ CD43+/CD23-/CD10-). The t (11;14) by FISH was positive in the unspecified B-NHL, making C-FCM more sensitive as a diagnostic technique than histopathologic study in this case. The t(11;14) was negative according to FISH, and cyclin D1 was negative with immunohistochemical techniques in the second case. A molecular study clarifying this discordance
